Sulfadiazine and pyrimethamine in the postnatal treatment of congenital toxoplasmosis: What are the options?

Expert Review of Anti-Infective Therapy

Volumn 1, Issue 1, 2003, Pages 175-182

  Petersen, Eskild ^a   Schmidt, Dorte Remmer ^a  

^a WHO REGIONAL OFFICE FOR EUROPE   (Denmark)

Author keywords

Congenital infection; Neonatal screening; Prenatal screening; Pyrimethamine randomized controlled trials; Sulpha; Toxoplasma gondii

Indexed keywords

ANTIMALARIAL AGENT; ATOVAQUONE; AZITHROMYCIN; CLINDAMYCIN; FANSIDAR; MACROLIDE; MEPRONE; PROGUANIL; PYRIMETHAMINE; SPIRAMYCIN; SULFADIAZINE; SULFADOXINE; SULFAMETHOXAZOLE; SULFONAMIDE; TRIMETHOPRIM;

BONE MARROW SUPPRESSION; CLINICAL STUDY; CLINICAL TRIAL; CONGENITAL TOXOPLASMOSIS; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG POTENTIATION; EYE INJURY; HEALTH CARE COST; HUMAN; NEWBORN SCREENING; PATIENT COMPLIANCE; PATIENT REFERRAL; PERINATAL PERIOD; PRENATAL SCREENING; PUERPERIUM; RANDOMIZATION; REINFECTION; REVIEW; STEVENS JOHNSON SYNDROME; SYMPTOMATOLOGY; TOXOPLASMA GONDII;

EID: 2942555449     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14787210.1.1.175     Document Type: Review

References (39)

1. Janku J. Pathogenesa a pathologika anatomic tak nazvaneho vrozenehonalezem parasitu v stinici. Cas. Lek. Ces. 62, 1021-1027 (1923).
2. Koch FLP Wolf A, Cowen D, Paige BH. Toxoplasmic encephalomyelitis: VII. Significance of ocular lesions in the diagnosis of infantile, or congenital toxoplasmosis. Arch. Ophthalmol. 29, 1 (1943).
3. Couvreur G. Etude de la toxoplasmose congénitale à propose de 20 observations. These. Paris, France,(1956).
4. Sabin AB, Warren J. Therapeutic effectiveness of certain sulfonamides on infection by an intracellular protozoan (Toxoplasma). Proc. Soc. Expr. Biol. Med. 51, 19-23 (1942).
5. Eyles DE. The present status of the chemotherapy of Toxoplasmosis. Am. J. Trop. Med Hyg. 2, 429-444 (1953).
6. Eyles DE, Coleman N. Tests of 2,4-diaminopyrimidines on toxoplasmosis. Pub. Hlth Rep. 67, 249-52 (1952).
7. Eyles DE, Coleman M. Synergistic effect of sulfadiazine and daraprim against toxoplasmosis in mice. Antibiot. Chemother. 3, 483-490 (1953).
8. Beverly JKA. A rational approach to the treatment of toxoplasma uveitis. Trans. Ophthalmol. Soc. UK78, 109-121 (1958).
9. Garin P, Eyles DE. Le traitement de la toxoplasmose expérimentale de la souris par la Spiramycine. Nouv. Press Méd. 66, 254-260 (1958).
10. Feldman HA. Congenital toxoplasmosis - a study of 103 cases. Am. J. Dis. Child. 86, 487-95 (1953).
11. Koppe JG, Loewer-Sieger DH, Roever-Bonnet H de. Results of 20-year follow-up of congenital toxoplasmosis. Lancet 254-256 (1986).
12. Petersen E, Dubey JP. Biology of Toxoplasmosis, In: Clinical Toxoplasmosis: Prevention and Management. Joynson DHM, Wreghitt TG (Eds). Cambridge University Press, UK, 1-42 (2001).
13. Scholer HJ, Leimer R, Richle R. Sulfortamides and sulphones. In: Antimalarial Drugs II. Peters W Richards WHG (Eds). Springer-Verlag, Berlin, Germany, 123-206 (1984).
14. Garin JP, Sung RTM, Mojon M, Paillard B. Guérison de la toxoplasmose expérimentale de la souris par l'association sulfadoxine-pyriméthamine. propositions d'application à l'homme. Lyon Med. 236, 19-23 (1976).
15. Phillips-Howard PA, West LJ. Serious adverse drugs reactions to pyrimethamine-sulfadoxine, pyrimethamine-dapsone and amodiaquine in Britain. J. R. Soc. Med. 83, 82-85 (1990).
16. Kavi J, Webberley JM, Andrews JM, Wise R. A comparison of the pharmacokinetics and tissue penetration of spiramycin and erythromycin. J Antimicrob. Chemother. 22(Suppl. B), 105-110 (1988).
17. Schoondermark VVE, Galama J, Camps W, Vree T, Russel F, Meuwissen J. Pharmacokinetics of spiramycin in the Rhesus monkey: Transplacental passage and distribution in the tissue in the fetus. Antimicrob. Agents Chemother. 38, 1930-1936 (1994).
18. Huskinson-Mark J, Araujo FG, Remington JS. Evaluation of the effect of drugs on the cyst form of Toxoplasma gondii. J. Infect. Dis. 164, 170-177 (1991).
19. Derouin F, Almadany R, Chan F, Rouveix B, Pocidalo JJ. Synergistic activity of azithromycin and pyrimethamine or sulfadiazine in acute experimental toxoplasmosis. Antimicrob. Agents Chemother. 36, 997-1001 (1992).
20. Bosch-Driessen LH, Verbraak FD, Suttorp-Schulten MSA, Ruyven RLJ, Klok AM, Hoyng CB, Rothova A. A prospective, randomised trial of pyrimethamine and azithromycin versus pyrimethamine and sulfadiazine for the treatment of ocular toxoplasmosis. Am. J. Ophthalmol. 134, 34-40 (2002).
21. World Health Organisation. Report of the WHO consultation on Public Health Aspects of Toxoplasmosis. WHO/CDS/VPH/88 [74]. (1988).
22. Remington JS, McLeod R, Thulliez P, Desmonts G. Toxoplasmosis. In: Infectious Diseases of the Fetus and Newborn Infant (5th Edition). Remington JS, Klein JO (Eds). WB Saunders, PA, USA, 205-346 (2000).
23. Silveira C, Belfort R, Muccioli C et al. The effect of long-term, intermittent trimethoprim/sulfamethoxazole treatment of recurrences of toxoplasmic retinochoiditis. Am. J. Ophthalmol. 134, 41-46 (2002).
24. Couvreur J, Desmonts G. Congenital and maternal toxoplasmosis. A review of 300 congenital cases. Develop. Med. Child. Neurol. 4, 519-530 (1962).
25. Wilson CB, Remington JS, Stagno S, Reynolds DW. Development of adverse sequelae in children born with subdinical congenital Toxoplasma infection. Pediatrics 66, 767-774 (1980).
26. McAuley J, Boyer KM, Patel D et al. Early and longitudinal evaluations of treated infants and children and untreated historical patients with congenital toxoplasmosis: The Chicago Collaborative Treatment Trial. Clin. Infect. Dis. 18, 38-72 (1994).
27. Guerina NG, Ho-Wen H, Meissner HC et al. Neonatal serologic screening and early treatment for congenital Toxoplasma gondii infection. N. Engl. J. Med. 330,1858-1863 (1994).
28. Fuchs HJ, Fledelius HC, Schmidt DR, Petersen E. A 6-year ophthalmic follow-up of children born 1992-1996 with congenital toxoplasmosis in Denmark. International Conference on Toxoplasmosis, Copenhagen 23-25 June (2003) (Abstract).
29. Villena I, Aubert D, Leroux B et al. Pyrimethamine-sulfadoxine treatment of congenital toxoplasmosis: Follow-up of 78 cases between 1980 and 1997. Scand. J. Infect. Dis. 30, 295-300 (1998).
30. Gilbert R, Dunn D, Wallon M et al. Ecological comparison of the risks of mother-to-child transmission and clinical manifestations of congenital toxoplasmosis according to prenatal treatment period. Epidemiol. Infect. 127, 113-20 (2001).
31. Foulon W, Villena I, Stray-Pedersen B et al. Treatment of toxoplasmosis during pregnancy: a multicenter study of impact on fetal transmission and children's sequelae at age 1 year. Am. J. Obstet. Gynecol. 180, 410-415 (1999).
32. Gras L, Gilbert RE, Ades AE, Dunn DT. Effect of prenatal treatment on the risk of intracranial and ocular lesions in children with congenital toxoplasmosis. Int. J. Epidemiol. 30, 1309-1313 (2001).
33. Gilbert R, Gras L, the European Multicentre Study on Congenital Toxoplasmosis. Effect of timing and type of treatment on the risk of mother to child transmission of Toxoplasma gondii. Br. J. Obsts. Gynaecol. 110, 112-120 (2003).
34. Couvreur J, Nottin N, Desmonts G. La Toxoplasmose congénitale traitée. Ann. Pediatr (Paris) 27, 647-652 (1980).
35. Wilson CB, Remington JS, Stagno S, Reynolds DW. Development of adverse sequelae in children born with subclinical congenital Toxoplasma infection. Pediatrics 66, 767-774 (1980).
36. Couvreur J, Desmonts G, Aron-Rosa D. Le prognostic oculaire de la toxoplasmose congénitale: rôle du traitements. Ann. Pédiatr (Paris) 31, 855-858 (1984).
37. Maisonneuve H, Faber C, Piens MA, Garin JP. Tolérance de l'association sulfadoxine-pyriméthamine. Vingt-quatre observations. Presse Méd. 13, 859-862 (1984).
38. Koppe JG, Loewer-Sieger, DH, Roever-Bonnet H de. Results of a 20-year follow-up of congenital toxoplasmosis. Lancet 254-256 (1986).
39. Hohlfeld P, Daffos E, Thulliez P, Aufrant C, Couvreur J, MacAleese J et al. Fetal toxoplasmosis: outcome of pregnancy and infant follow-up af-ter in utero treatment. J. Pediatr. 115, 765-769 (1989).